Celldex Therapeutics (CLDX) Short-term Investments (2010 - 2026)

Celldex Therapeutics' Short-term Investments history runs 17 years deep, the most recent figure standing at $415.7 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 36.64% year-over-year to $415.7 million in Q1 2026; TTM through Mar 2026 was $415.7 million, a 36.64% decrease from a year earlier, with the FY2025 full-year figure at $489.7 million, down 29.73% from the prior year.
• Short-term Investments retreated to $415.7 million in Q1 2026 per CLDX's latest filing, from $489.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $759.6 million in Q2 2024 and bottomed at $214.2 million in Q3 2023.
• The 5-year median for Short-term Investments is $415.7 million (2026), against an average of $465.7 million.
• Across the five-year window, Short-term Investments plunged 36.86% in 2023 and soared 238.38% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $275.5 million in 2022, then surged by 41.11% to $388.8 million in 2023, then soared by 79.26% to $696.9 million in 2024, then retreated by 29.73% to $489.7 million in 2025, then decreased by 15.11% to $415.7 million in 2026.
• Per Business Quant, the three latest CLDX Short-term Investments figures stand at $415.7 million (Q1 2026), $489.7 million (Q4 2025), and $547.2 million (Q3 2025).